Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Inhibrx, Inc. (INBX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
24.73+1.89 (+8.27%)
At close: 04:00PM EDT
24.73 0.00 (0.00%)
After hours: 04:32PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close22.84
Open22.84
Bid9.89 x 1100
Ask24.73 x 1400
Day's Range20.56 - 25.19
52 Week Range7.67 - 47.90
Volume501,298
Avg. Volume491,169
Market Cap965.392M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INBX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inhibrx, Inc.
    ITOS: Rating decreased to a HOLDITEOS THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • Benzinga

    Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

    Inhibrx Inc (NASDAQ: INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited condition that raises lung and liver disease risks. AAT is a protein that protects the lungs, and the liver makes it. Treatment was well tolerated, with no severe or serious adverse events related to the study drug. Related: Inhibrx Shares Interim Data On INBRX-106 - Keyt

  • Zacks

    Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates

    Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Zacks

    Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates

    Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement